Business Wire

WESTERN-UNION-COMPANY

17.9.2020 15:02:34 CEST | Business Wire | Press release

Share
Western Union and Isabel Group team up to provide international payment services to Belgian companies

Western Union, a leader in cross-border, cross-currency money movement and payments, announces a collaboration between its business division, Western Union Business Solutions , and Isabel Group , the leading provider of multi-bank services for both businesses and consumers and largest Fintech in Belgium.

As part of its partnership, Western Union Business Solutions will provide worldwide connectivity to Isabel Group’s multi-banking platform that enables organizations to manage their banking online and perform quick and easy payments. The Isabel 6 platform serves 70,000 professional user clients, and now collectively may access Western Union Business Solutions’ unrivaled global payment network across over 200 countries and territories in more than 130 currencies around the world. Western Union Business Solutions’ extensive global network, combined with knowledge of local markets, will help enable Isabel platform users to manage international payments simply, effectively, and efficiently. The expertise of Western Union Business Solutions’ foreign exchange specialists on currency fluctuation and foreign exchange markets will assist clients in managing international payments and foreign exchange risk through a wide range of hedging product offering.

Marc-Elie Caspar, country director France & Benelux at Western Union Business Solutions, notes:

“We are proud to extend and accelerate our presence and activities in Belgium through this key partnership with Isabel Group, the largest Fintech player offering the most popular B2B multi-banking ecosystem and online payment solution for companies of any size in Belgium. Together, we will offer our customers an innovative payment solution for foreign exchange transactions, dedicated customer support, negotiated rates and fees and an outstanding level of trust thanks to our European banking license.

“This type of partnership is part of our DNA at Western Union Business Solutions. We equip and support organizations around the world that are looking for a partner to optimize cross-border payments with solutions for sending, receiving, and managing international payments.”

The Isabel 6 platform is backed by the expertise, resources and technology provided by Isabel Group. The Belgian fintech has an extensive network of partners and is one of the three companies in Belgium (source: AMPG) to meet the requirements of the ISO/IEC 20000-1 2011 standard and to have obtained the certification corresponding to this standard.

Jean de Crane, CEO at Isabel Group, adds: “We are happy to welcome Western Union Business Solutions as a new international member on the Isabel 6 multi-banking platform. This collaboration will add value to our mutual business customers in the processing of their payments and foreign exchange strategies. We are looking forward to working together with this international player in our ecosystem.”

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of June 30, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .

About Isabel Group

Isabel Group links and streamlines the administrative and financial processes of businesses. The financial services provider ensures a smooth and reliable exchange of documents, payments, and identities, and automates access to them. This helps businesses to gain insight into their financial flows and make better business decisions.

Some 65,000 businesses, 3,000 accounting firms, 150 software partners, and 30 banks are working with or linked to Isabel Group’s software: Isabel 6, Seven, Ibanity, CodaBox, ClearFacts, Ponto, BookMate, SignHere, KUBE and Zoomit. This means that Isabel Group is managing Belgium’s most extensive financial infrastructure. With more than 300 experts, the group automates 450 million transactions per year or 7.10 billion euros per day.

WU-G

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye